Cidara Therapeutics has filed a patent for compositions and methods to treat bacterial infections caused by Gram-negative bacteria. The patent involves the use of conjugates containing an Fc domain linked to cyclic heptapeptides. The abstract provides an overview of the patent, while the claim has been canceled. GlobalData’s report on Cidara Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cidara Therapeutics, nanoparticle drug conjugates was a key innovation area identified from patents. Cidara Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of bacterial infections using conjugates with cyclic heptapeptides
A recently filed patent (Publication Number: US20230190950A1) describes a conjugate that is represented by formula (D-Ia). The patent also includes various other claims related to the conjugate, such as different formulas (D-II, D-IV, D-V, D-V-1, D-V-3, D-V-6, D-V-8, D-VI, D-VI-1, D-VI-3, D-VI-6, D-VI-8, D-L-I), and the use of the conjugate in pharmaceutical compositions and methods of protecting against or treating bacterial infections.
The patent claims cover a conjugate represented by formula (D-Ia), as well as other related formulas (D-II, D-IV, D-V, D-V-1, D-V-3, D-V-6, D-V-8, D-VI, D-VI-1, D-VI-3, D-VI-6, D-VI-8, D-L-I). These conjugates can be used in pharmaceutical compositions for protecting against or treating bacterial infections. The patent also mentions the use of the conjugate in the form of a dimerized Fc domain when n is 2.
The patent provides a wide range of options for the composition of the conjugate, including various alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, cycloalkylene, heterocycloalkylene, cycloalkenylene, heterocycloalkenylene, cycloalkynylene, heterocycloalkynylene, arylene, heteroarylene, O, S, NRi, P, carbonyl, thiocarbonyl, sulfonyl, phosphate, phosphoryl, or imino groups. The Ri group can be H or various alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, heterocycloalkynyl, aryl, or heteroaryl groups.
The patent also mentions the use of the conjugate in pharmaceutical compositions, which include a pharmaceutically acceptable excipient. These compositions can be used for protecting against or treating bacterial infections in subjects.
In summary, the patent describes a conjugate represented by formula (D-Ia) and various related formulas, which can be used in pharmaceutical compositions for protecting against or treating bacterial infections. The patent provides a wide range of options for the composition of the conjugate, including different groups and substitutions. The patent also mentions the use of the conjugate in the form of a dimerized Fc domain. The patent further includes claims related to the use of the conjugate in pharmaceutical compositions and methods of protecting against or treating bacterial infections.
To know more about GlobalData’s detailed insights on Cidara Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
